Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Nicolini FE, et al. Leuk Lymphoma. 2012 May;53(5):907-14. doi: 10.3109/10428194.2011.627480. Epub 2011 Dec 5. Leuk Lymphoma. 2012. PMID: 22023530 Clinical Trial.
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S. Nicolini FE, et al. Leuk Res. 2007 Jun;31(6):865-8. doi: 10.1016/j.leukres.2006.12.003. Epub 2007 Jan 8. Leuk Res. 2007. PMID: 17208297 Clinical Trial.
[Treatment of chronic myeloid leukemia in 2007].
Labussière H, Hayette S, Tigaud I, Michallet M, Nicolini FE. Labussière H, et al. Among authors: nicolini fe. Bull Cancer. 2007 Oct;94(10):863-9. Bull Cancer. 2007. PMID: 17964980 Free article. Review. French.
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Müller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH, Apperley JF, Yagasaki F, Pearson JD, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman JM, Zhou W. Nicolini FE, et al. Blood. 2009 Dec 17;114(26):5271-8. doi: 10.1182/blood-2009-04-219410. Epub 2009 Oct 20. Blood. 2009. PMID: 19843886 Free PMC article.
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M. Nicolini FE, et al. Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3. Leuk Res. 2011. PMID: 20605207 Clinical Trial.
Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.
Joha S, Dauphin V, Leprêtre F, Corm S, Nicolini FE, Roumier C, Nibourel O, Grardel N, Maguer-Satta V, Idziorek T, Figeac M, Laï JL, Quesnel B, Etienne G, Guilhot F, Lippert E, Preudhomme C, Roche-Lestienne C. Joha S, et al. Among authors: nicolini fe. Leuk Res. 2011 Apr;35(4):448-58. doi: 10.1016/j.leukres.2010.07.012. Epub 2010 Aug 3. Leuk Res. 2011. PMID: 20684991
198 results